Hi everybody, Joe for jaspyscasewrakes.com coming at you with 2022 Panini Dauners baseball eight box Halfcase pick your team number two with three boxes being given away. That's from a different case if you follow the instructions here No vet common ship all non sports cards will be randomized for example the The San Diego chicken and I think there's one other there's one other person But whether they're relics or autos or numbered cards gonna group all of those and there's not a lot There's a room group all those into one lot and randomized to one person in the break I don't think we've even seen any yet to be honest with you, but Just keep that in mind. All right big. Thanks to everybody here who picked their teams Think we did it got it straight up. No filler which I appreciate Seem flat ended up with that last spot mojo a's And let's pop these boxes open remember I marked those with a blue X right there So we all know it's from the same case three autographs or memorabilia cards per box on average and of course we'll do a little Autograph and relic recap at the at the end along with any You know, maybe low-numbered cards many ten or less or something like that and in the Got a little basketball on the background Celtics up 48 29 so a big bounce back game for them Okay If Robert Runkle is in the chat Think well our our team sent you a Our shipping team or someone sent you an email that they need a response So case you're listening in the background Got a got a big slate of baseball games here on a Tuesday Looks like the couple of some games postponed. I'm assuming due to weather We've got yeah, inclement weather pirates tigers are postponed and Padres at Guardians post a couple games in progress Baseball wise the Diamondbacks leading the Marlins to nothing in the bottom of the fourth in Miami In Philadelphia Philly's got a 3-2 lead on the Rangers The end of the third inning in New York Be a good matchup good series in New York the Mets up to nothing on the Braves Top of the fourth some other games I think it's double-header to Braves second game of the double-header Twins Orioles at zero just top of the third few innings in Yankees in Toronto zeros Bottom of the third Angels Red Sox zero White Sox Cubs just started bottom of the first scoreless Bottom of the first Reds Brewers scoreless the first game of the double-header the Mets won five four looks like It's like Pete Alonzo had a couple RBI singles Pounced on Charlie Morton a little early there, too I think I heard or read somewhere that that as of the start of the day today It's the first time in history that the the two Southern California teams the LA area teams and two New York City teams First time they've all been in first place at the same time At least since they redid those divisions There's Wilson Contreras To 249 and we'll sleep and topple it all just in the interest of time We're gonna just show them to your team. We'll take care of it. There's Salvador Perez fire emoji to 75 So these are the commons that won't be shipping that will obviously ship rated rookies will all ship You know different parallels like that these two will of course ship So I feel like you're gonna be getting most of these cards anywhere. There's Max Scherzer Mets addition to 50 United States emoji emoji print tie France to 2022 I think he's a Maybe at the start of the day leading the league perhaps in RBI's What a Nolan Aaron Otto unleashed 604 to 999 got a 2022 Peter Lonzo diamond Kings Byron Buxton Got a diamond Kings to tease junior blue parallel not numbered, but of course will ship So I'll be breezing by those blue parallels like that one that'll ship, but not numbered And we've got Hans Krause blue autograph R numbered four out of 99 signature series auto That is for the Phillies Rick T With the fight and fills this Kyle Seeger to 2022 Chad Dawes favorite player how Seeger We got I think the Statue of Liberty emojis are one per box There's Chris Bryant Giants addition to 999 Miguel Cabrera to 2022 Brandon Marsh Wilson contenders brand belt the 2022 and There is another autograph of Philadelphia Luke Williams Signature series for Rick. You got Chas McCormick to 2022 a Juan Soto hit list to 349 It's a cool pattern Patrick Wisdom to 2022 I think he's getting the start tonight. There is Rod Peru twins addition to three 315 looks like and the relic is laser show Dustin Padrella 60 out of 99 that is for the Red Sox It's gonna go to Terry Boston Logan Webb to 2022 Next box. All right the next one. What other matchups do we have tonight? Mariners at Astros Chris flexing versus Christian Javier We got Dakota Hudson facing Brad Keller in Kansas City Washington has Eric Fed on the mound versus her Mon Marquez in Colorado and Oakland rays have Ryan Yarborough, maybe an opener called Blackburn and Giants at Dodgers. I should be a big and that's a TVS game for the national audience I Wonder if that's a TVS exclusive or if I could still watch The Dodgers Network, but Carlos Rodone versus Julio Urias Carlos Rodone and got a 117 era really worries not doing too bad either here to five era Dodgers are favored in the game although Divisional dogs tend to do divisional road dogs tend to do okay. They're looking for value And the over under is seven runs and it could be a pitching duel could be like a Two-one game or something like that We do have a poll posted right now This is a baseball break. It's a little bit of a longer break We kind of kind of float around discussion topics who wins game two between the Warriors and the Grizzlies against the spread if you'd like Warriors minus two Road favorites box two at Ozzy Aldi's elite series to 999 you Darvish to 2022 and what do I hear? Nice superstar scribbles Shane Bieber the Beams That is for Patrick and the Guardians Cleveland. This is for you. I see yeah, not numbered, but I don't think I've seen that parallel or that set yet superstar scribbles Colton Wonke even at 100 it's to 100 and we've got a out of 249 Jacob DeGrom diamond marvels Joe Morgan to 2022 It's nice one for the Mets. That's gonna go to Rick Rick s in the Mets diamond marvels Jacob DeGrom He's on his way back. I think Should be back. So that's gonna be Do the do the Mets even need him back? There's Brian Della Cruz to 2022 Mets have been playing some great baseball. I think that's what they expected of the Mets last year We got Drew Ellis signature series for the snakes Roadie with the diamond backs Diamond Kings Josh Donaldson to 2022 Statue of Liberty Jaren Duran, and we got a wander Franco trending insert to 349 John McCall with the rays Excellent start to the season for wander Franco We're looking at his numbers yesterday really good. Hopefully he keeps it up. Shamanaya still lays addition here to 2022 Cal Quantrell It's a 241 Holy Belanger start off the season cold had a really hot week and then has had a really cold week So kind of up and down for him 2022 Tyler O'Neill I think he's kind of settled into a swing It's Vlad Guerrero, Jr. At bats have been pretty good still been getting on base with some walks here and there Hopefully has a good May Jared Walsh a little bit of a slow start for him. Hopefully he heats up and there's Toronto's Gabriel Moreno That is to 999 I thought that was gonna be a lower number Joseph with the Toronto Blue Jays There's a wander Franco radio rookie Rex. What's going on? Uh, is Jordan Oliver is 2020 you see milgills to know having time have surgery What's time have surgery? there's wander Franco rated rookie Wonder if Rex was trying to say Rex has got to work on his typing skills here Uh, there's Frankie Montas to 2022 Having to have surgery. What kind of surgery? It's Joey Votto 34 out of 99 That's for Cincinnati. That's gonna go to Jeremy Harder and the red legs That's not good. How long are you gonna a meniscus tear? So some sort of knee issue? How long is he supposed to be out? It might be a little bit of adversity for the for the twins who started off The season doing pretty well. He's in a Byron Buxton injured as well Has a little bit of a knock Yeah, twins are a twins are 14 and nine on the season going into this game with the warriors They're still scoreless at the top of the fourth Looks like they have so far. We have 87 percent of voters are saying that That golden state minus two road favorites are going to win Overwhelming camera there looks a little dark, right? According to twins manager Rex is reporting that there's no timetable on a Miguel snow return But could be could be a season ending injury. Yeah, thus far Over 17 games so Noah's been uh, yeah struggling Maybe that knee has been bothering getting under 100 only one home run a few rbi's All right next box. Good luck Sandman to 2022. Wander Franco blue Whitmerefield to 999 I think we've seen too many rated rookie parallels For Wander Franco. So there you go, John not numbered Pretty nice good-looking card It's Kyle Tucker to 400 Austin Hayes to 2022 And there's bomb squad rice harper to 349. It's a cool-looking insert. I like it going to uh Rick T and the Phillies Cal Raleigh to 2022 Josh Donaldson to 2022 And we got Boba Shett piece of his jersey going to Toronto That'll be for joseph and the blue jays first Bryant kershaw Jared Kalanek To 41 3 out of 41 for the mariners that'll be for steven flat And we've got Eli Morgan For the guardians patrick davis Cleveland this is for you Got john means to 100 keeping it 100 He's getting Tommy john. So Long road back for him. Gavin sheets Byron buxton trending to 99 for the twins Jose Ramirez to 2022 Babe Ruth to 2022 Jazz Chisholm trending to 99 Matt Chapman to 2022 Carlos Correa to 2022 Apologies to these cards here. We've got down here erin ashby Barry Barry Roberts with the brew crew I think part of that ashby family if I'm not mistaken. Maybe I am but I'm pretty sure he is There's Sal Perez to 2022 I'm Sean Minaya I Doesn't say on the back of the erin ashby card, but For he's related to either Andy or alan All right Next box About this far into the break terry That far into the break and looks like after a little groin strained scarrow ties back in the Shoyo ties back in the angels lineup set to pitch on thursday Reds placing the slumping joey vado onto the kovid il Clevinger's return pushed to wednesday after the reina dodgers unveiling the mlb all-star game plan spending Santa Monica pier to cities downtown I'm in Santa Monica. I'm near the pier from the stadium to the sea It's according to the associated press the Los Angeles Dodgers available plans Tuesday That was earlier today for the summer's mlb all-star game the franchise's first time as a host in 42 years When is it? Early july, I think july 19 Dodgers have been scheduled as a side 2020 before the kovid pandemic shortened the season the game was canceled Last year's all-star game was in denver the stadium la live in downtown los angeles and Santa Monica pier Located 18 miles west of chavez ravine will be the backdrops for the event starting with july 15 No city and no fans have supported their team like the dodgers fans have team president san cashen said They're hungry for this game. They're very excited that they're gonna have it The all-star game is july 19 I hope I make it dodgers ace clayton kershaw said an eight-time all-star all the road teams that come in Get to play here. They say what a great place. I'll say is we're excited to share it Capitalizing on the 42 years since they hosted the dodge will be honoring jackie robinson In number war number 42 when he broke the color barrier for the franchise 75 years ago His widow rachel turns 100 on the day of the all-star game So a lot of uh opportunity that came from jack and all the other players that kind of came through dodgers Right fielder mookie vett said the future's game and the celebrity softball game We played on a saturday for the first time The home run derby is july 18th the same day workouts will be held The play ball ballpark The play ballpark will be set up at la live Featuring baseball and softball music red carpet for the all-star players and their families To strut their stuff before being shuttled to dodger stadium some indoor events will be nearby the convention center Oh and the mlv draft Uh begin sunday night on outdoor plaza on an outdoor plaza at la live. There's a lot of things happening here Then from friday through saturday at the sandamonic pier nearby beach fans can attend free events include instructional youth baseball softball daily yoga classes baseball themed sand sculptures batting cages set up on the pier mlv will join heal the bay to stage a beach cleanup on July 16th, which is all right. All right. Okay, check those out I'd like to see some baseball related sand sculptures Seems kind of cool It's kevin gossman to 500 and there is another unleashed car this time to 99 rafael devers Something else you just read on fan graph rex saying 202 pictures in 2017 at tommy johnson 19 didn't didn't play at all that See supposedly 26 percent of pictures in in the history. I've had it Yeah, that makes that makes sense. It's josh johnson 2022 There's greg deekman for the cubs Obviously tommy john it's more they can identify that a lot more easily nowadays And with the surgeries being so successful At a high success rate. It's not like a Scary thing anymore. So I think more players are opting into it I feel something it's awesom haze 2022 And look at this 7 out of 25 showy otani bomb squad The 19 of that's for the angels by the way rick rick s with that one the 19 of them didn't play at all that season Seems like a weird way to put that Because most of the time aren't you going to lose the season if you have tommy Supposed to I suppose it's I suppose it comes down to when you get tommy john obviously There's cal raleigh. It's 2022 under how many non-pictures get tommy john i I don't think it's as common Because most players actually You know just With the repeated motion you are going to have ligament issues So most pictures are going to have some sort of ucl terror in their arms most ball players will but obviously position players Aren't aren't throwing that often so they could easily play through it without losing anything Corey seager though did get I think tommy john surgery But the recovery for position players is a lot more quick I think for pictures. I think it's like it's pretty much 12 months Position players get I think if I want to say it's half the time There's seth beer for arizona brody. I think that's the reason That's a reason for taking pictures out of the game earlier Well, probably yeah, probably just for injury, but You know, I think they've been taking pictures out of games earlier for last decade It's babe ruth 20 maybe maybe more but I think Taking pictures out earlier I don't know if tommy john is really the overarching it is probably a reason but just overall health not specifically tommy john but I think uh, I think it's just strategically Right. Yeah pictures aren't going past the seventh inning, but yeah, that's been a trend for a long time This is not nothing nothing new so Yeah, that's not that's not a new thing rex But it's I think more and more statistics have shown that if you go through You know most pictures You know, there's alec bong relic for rick tea and the fillies most pictures Once they see the order a third time, which is usually six seventh inning or so um Hitters do significantly better against them. So that trend the last 10 15 years has been uh Has been hey you take them out beforehand The fresh reliever arm in there's it's a 999 oakland edition of matt olson And so that specialized reliever has definitely Been a reason why There's a jake berger rated rookie to 25 nice low number there So that's been happening for a long time This year is even earlier right and why is that? Short spring training a lot of pictures have not been stretched out yet Jeremy harder with the white socks So yeah a lot of pictures only going maybe four or five innings as they kind of get Early on in their first few starts as they're as they're getting their pitch counts up, you know, so They got to get they got to get their pitch. So a lot a lot of times players are getting into like 75 80 pitches By the fourth fifth inning so they're they're getting pulled a little bit earlier so everyone kind of Everyone kind of knew that with that short spring training it's going to probably affect well I think it affects everybody I think hitters some some hitters may need a couple extra weeks of spring training to get Um, you know just to get some timing down pictures definitely need to get their arm strength up You know, so when when people were up in arms over clayton kershaw Not having the chance to Having a chance to throw a perfect game you know As a fan, I'd want to see it but but you know Kershaw who had some elbow issues last year Avoided surgery didn't even pick up a baseball until january Had a short spring You know and wasn't really throwing any competitive pitches until Maybe he got one or two starts and maybe got stretched out to 50 60 pitches So then you get what first start of the year Kind of cold minnesota, you know at that point you kind of understand why that decision was made I think by may you should probably start seeing Seeing pitchers kind of fully stretched out. I think most starters should have Should have their third or Should have like their third start under the belt belts for most Third or fourth start so By like fifth or sixth starters, so I think you're gonna start to see uh start to see pitchers more Stretched out and more comfortable In the in a In a good groove right Yeah, imagine if kershaw got injured Well, it's you know, if you're a manager, you can never win, right? There's tre mancini to 2022 If you leave him in and he gets injured You know you get crushed for that. Why didn't you take him out earlier?  There's camilo de val san francisco giants john mccall with my rivals I think that's number john, but here's your signature series auto It's charlie blackman to 2022 Here's max muncie trending To 349 for the Dodgers Kyle schorber 2022 still uh, that's a little boston edition there Joe ryan and there's plate and kershaw It's tom terrific to 2022 The original and we got a brendan mckay relic He's still battling back from some injuries. He was supposed to be sort of a two-way A two-way player like otani, but he was not really Materialized as of yet There's a nice dodger's prospect andy pogis to 999 Zach wheeler to 500 Louise robert to 2022 We've got lance mccollars alec manoa who i think Is starting right now Both flows variation Lake snell keeping it 100 to 100 And there's a mike trout Diamond marvels to 249. These are pretty cool That'll be for rick s and the halos The brand lau to 2022 Yelich and the wander franco rated rookie This lance lin to 46 john with the rays And we got a gavin sheets autograph nice.  No, it was a burger reaching on infield single scoring a bray you Maguire sacrifice And then uh ending later at tim anderson homeroom solar shot Sheets 0 for 1 on the day josh hater I think already had double digit saves for josh hater. It's pita lanzo carlos korea elite series to 999 pk zimmerman 2022 There's a mitch hanager. I think just Stars parallel but not numbered and there's brandon crofford right there All right next box All right. All right. All right onwards. So a's activate lou travino from the il We saw the vato news. He's on the il add they activate tyler stevenson animal sanchez on the 60 day I l rex talked about the miguel seno surgery Uh angel's option joe adel, huh? Hmm. That's disappointing So angel announces after the option outfielder joe adel triple a salt lake utility man joseo rojas Has been recalled to take a spot in the act of roster adel's been considered one of the sports most talented young players from time According to mlbtrade rumors.com baseball america slotted him Among the top two prospects in the angel's system every year between 2018 His first season being selected 10th overall in the previous draft in 2021 when he exhausted his prospect eligibility heading into last year baseball america ranked him the game's 13th best prospect evaluators raved about his combination of power and speed But the 23 year old has yet to establish himself at the major league level during the 2020 shortened season Uh, he broke into the majors played 38 games flashed 161 2 12 and 266 He spent the first half of last year on optional assignment beginning the season at the alternate training site went to salt lake Through the end of july he was hitting better so, yeah He broke camp with the big league club this year, but has gone off to disappointing start Through uh 66 plate appearances hitting 231. He's slashing 231 242 431 three home runs four doubles have led to a reason respectable slugging output But particularly in the context of a brutal offense among league y but he's punched out 24 times while drawing just a single walk And he's been rough defensively too He's just gonna have to have to figure some things out. I guess Mr. Jaren diran diran to 220 for the red socks there's kettle marté to 75 fire emoji You know what i've not seen any sandigo chickens Here's the 149 boba shed Those non The the cards that are not associated with the baseball team will be randomized as one lot to one person in this group But we have not seen any I think there's only two names on that on that checklist, but No, there's zack wheeler to 2022 There's austin reilly to 2022 And there's josh hater He's of his jersey. Yeah, and no is that the other the other person domingo There's a domingo iala who does all a lot of the youtube baseball videos There's hater for the brew crew and that'll be for Uh, berry berry roberts jim tome to 2022 There's the hit list to maderson Uh, that is to 999. He's got a solo shot today Tyler maley Uh to 210 Pops we are willy sargent Lance lin to 2022 And we've got a johnson stiver Retro autograph for the white socks. That's going to go to jeremy h frank thomas to 2022 and another blue wander franco rated rookie Having a great season already Hope he keeps it up And we've got a unleashed rhino ryan samberg to 349 jade mccarthy 2022 christian yellich to 500 And we got a vedal brujan 70. Uh, yeah 75 out of 99 for john and the rays Yeah, they really do the marvels unleashed Bomb squad we saw a really cool. I'll show you in the recap But we saw a really nice otani bomb squad to 25 So they had like an aqua background It's 2022 azi albies, which I thought looked really sharp I don't know what those go for on the secondary market, but I'm sure Just looks nice visually. O'Neill cruise to 999 johnson india 2022 And kershaw blue parallel color match All right two boxes to go no worries rick Have you looked that up on the secondary? What does that go for? I mean regardless of the valley. It's a cool a cool card We have not seen a whammy card yet. Is that what they're called a whammy card? That that insert is is really short printed. This may be It'll be one or two per case Actually, we did see two in the first half Let's see if we can see a third in the second half And I know they're not super common Yeah, no rush. I'm just I was just curious see what that otani could go for Maybe it wasn't yesterday. I put all the great cards yesterday. Wow rick is saying uh is saying 13 bids on an otani Bomb squad to 25 13 bids already at 282 dollars. That'll cover the spot By the time that auction is over it'll cover the spot for sure Score updates any changes here? Yeah diamondbacks stretching their lead to five nothing bottom of the six over the marlins Rangers and fillies are tied at three mechs still have a three nothing lead in the top of the seventh over the braves Twins have a two on lead on the o's and the fifth blue jays a one zero lead on the yankees Yankees have only been one hit They've been one hit through five Well, that's a sold price 208 is still good Still good. I like it Alec manoa I don't know. I know the picture market picture market not as good as the hitting market, but alec manoa Could be a big name In the hobby if he keeps pitching like this Through five He's one hit The yankees who've been hitting the ball really well no earn runs seven strikeouts Doesn't look any walks. I don't think I don't think any walks either Maybe one walk. It's pretty good 72 pitches 41 for strikes Looks like you could probably go a couple more innings Clayton kershaw dominators Yeah, I agree mpk. It seems like the the Seems like the the short printed inserts that you could find in here I've created a really nice chase And a really good value for these dawn responses. I don't think we have another break after this, but We'll dig up some more of this dawners baseball. So keep your eye out on jazby's casebreaks.com diamond kings to tis jr to 2022 And we got will clark will the thrill John with the giants Yeah, he had a pretty cool Pretty cool swing my cousin The cousin dan is a lefty kind of emulated that uh and will clark batting stance and a plate Freddie peralta one of one Nice. Yeah, he can strike out a lot of guys pretty cool and uh Brewer, I don't know why I blanked on that for a second, but brew crew That's gonna be for barry roberts barry printing plate All aboard the big hit express Out of fives and under Get the train whistle Didn't have the team name on there for a second. We got illa hymenes to 249 elite series I think he's out for a little bit with uh with an injury As Kyle Muller to 2022 Terry saying people are going nuts over McGill cards The the met There's yachty to 75 fire emoji And there is riley adams Uh for the gnats that's gonna be jacob glenn with the nationals Matt Olson to 2022 There's the frank thomas unleash to one uh to 999 Trust me. She'll like it too Trevor Hoffman to 2022 Pretty incredible change-up from that guy There's another wander franco rated rookie card Going to john and the rays Robbie ray to 2022 that is seattle edition And we got a colton welker For the rockies that's going to go to jeremy And the rocks was actually You know kind of surprise surprise me. They had a pretty decent start to the year Let's see if that's sustainable, but Rockies a good start to the year It's trey turner hit list To 999 for my dodgers It's gonna go to justin glad to grow junior to 2022 And we got a cross town rivals In sir, we'll do a left right randomizer on that There's yellich to 2022 I mean, I'll just do a team random on that Corbin burns To 234 brandon marsh. I feel like I've not seen a lot of those cross town In fact, I would even argue that that's the first cross town rivals card that I've seen So that's a cubs white socks randomizer. Actually, no We're waving off the randomizer. We're waving off the randomizer Jeremy Harder has both the cubs and the white socks and It's got both. So there you go, Jeremy I don't know how short printed that is but I feel like we have not seen any so Up to this point at least not in the first half anyway So that might have some sneaky good value there We made it final box It's gonna clock in just a little over an hour Thanks, everybody. Let's check in on the uh Let's check in on the basketball score. Yeah Celtic still leading comfortably They outscored the Bucks 32 21 In the first quarter they outscored the Bucks 33 to 19 In the second quarter Still doing the three box giveaway Why wouldn't I carry Imagine if I just said nah not anymore We're gonna you're gonna Take the rug out from under you People would ride No, there was no deadline on that. That's still I think it's still in the title Of the discount still in the title pick your team two three boxes given away need two plus teams If there's a if there's like a deadline Will uh We would we would put that explicitly in the description And in fact, that's why you can notice on my face camera. That's why I've got a few boxes right over here Yeah, and if it's another if it's like uh If it's another if it's a deadline related thing like at the end of the night I would have taken out the three boxes given away or something like that So it wouldn't still remain in the title just for future efforts The tonight a tonight only situation Doesn't happen too often, but if it does it'll it'll happen With like hey, we're giving away a couple spots within the break or something like that All right final box ladies and gentlemen. Good luck And uh, thanks for getting in thanks for making all this happen. We appreciate it We'll we'll dig up some more Donner's baseball for you. So get into it next time you see it. Don't miss out That unleashed Ken Griffey Jr to 349 Logan Gilbert great season for him too great start 2022 There's Alec Minoa. That'll ship Chris Bassett a's edition 2022 and behind Andre Jackson is Is there's the Alex? There's on hell zerpa For the Royals rick s with kc There's our Zerainia to 2022 Cedric Mullins to 999 There's Bert Blilev into 2022 Max Muncie to 2022 And a Jose Reyes Relic for the Mets rick with that one as well Jeremy Harder saying that cross on rivals card is a super short print beautiful card Nice Any idea what that's going to go for? A couple nice players on there And a nice Julio Rodriguez rated prospect Hard to 999. No, I haven't seen any downtowns But the uh, I think the whammy card is like is like a one or two per case sort of situation There's a cool otani in here that I'll show you in a second The otani was bomb squad otani to 25 a little bit of an aqua background um Rick Serrano looked it up and said it was like already sold for like a few hundred dollars Hit hit list Yuli Gurriel to 99 And the marvels are nice as well It's Jake Myers 2022. Let's see if there's any other low number stuff we can get Frankie Montas to 75 he Is a popular trade target. I want to say Lucas Geolito to 2022 And another Aaron Ashby autograph for the brew crew that'll be for Barry Roberts There's Nate Lowe to 2022 Nate Lowe and Brandon Lau the thing used to be on this on the raise together All right gang, we're gonna give away a few boxes and then we'll do a recap But first Who's gonna win those boxes? Let's flip back over here Sort by your first name So if you bought at least two teams Get one entry four teams two entries so on and so forth If you follow those instructions, you got a chance of winning a sealed box Barry bought two teams. That's an entry Brodie bought two teams. That's an entry Jacob two teams That's an entry Jeremy bought four teams. That's two entries John bought two. That's an entry Joseph with two. That's an entry Justin with two. That's an entry Uh, Patrick with two. That's an entry Rick s with four. That's two entries rick t with one. That's an entry Stephen flat with two that's an entry, Terry with two that's an entry, Travis with two that's an entry. I think every single person got an even number of teams because there's 15 entries perfect thank you. So new dice fresh list so it's gonna be let's roll the dice we're gonna randomize that list five and a two lucky seven times. Top three after seven gets a sealed box. Good luck. One, two, three, four, five, six, and fingers crossed seventh and final time after seven. John, Terry and Jacob after seven times lucky seven congrats to you a sealed box of Donner's baseball going your way. It's probably gonna be shipped separately from your from your hits so that might come a little bit later. But congrats to the three of you. Alright hey let's check out the break not too shabby at all. Got the nice crosstown rivals some Wanderfrankos that printing plate for Milwaukee, blue Wanderfranko, Gavin Sheets, that Jake Berger was a 25. There's that out of 25 bomb squad that looks really sharp. I gotta take a picture of that just visually it looks really cool. More Wanderfranko blue, Wanderfranko trending, Shane Bieber, Superstar Scribbles I think it's the first Superstar Scribbles that I've seen. Luke Williams and Hans Kraus started things off for us. There you go gang I'm Joe for jazby's casebreaks.com thanks for watching thanks for breaking with us and I'll see you next time for the next baseball break. Bye bye.


Minnesota Governor Mark Dayton says he will appoint someone to fill L. Frankens US Senate seat in the next couple of days. Dayton is not commenting on candidates he is considering, but associated press sources say Lieutenant Governor Tina Smith is his preferred choice and that Dayton is under pressure from top Washington Democrats to appoint more than a placeholder to fill Frankens seat. The pressure surrounding Frankens replacement has Smith now considering a run for the office in 2018. That's according to a Democratic official and another Democratic operative who were not authorized to talk about the discussions. Franken announced his resignation on Thursday. If you've enjoyed this segment of Lakeland News, please consider making a tax deductible contribution to Lakeland Public Television.


I have my care plan. So I thought today we could go through my care plan and share some thoughts. Now I haven't registered yet but I'm going to diagnosis, EUPD, PTSD, depressive disorder, eating disorder, bipolar-affective disorder, arthritis, type 1 diet, medications, lithium ethyl thousand milligrams nocturnal, haloperidol, 5 by twice daily, tracidone 50 milligrams a night, vortiocetine 20 milligrams daily, precyclozide 5 milligrams twice daily, colinazepam 500 milligrams micrograms, biobuine, benzoplasal, glycozide, amphibiphozin, desidestral, follic acid. We have discussed tattoos on her arms which she is pleased. We discussed the benefits of a care quarter later. She's got paid epipheries and bought any camera lens for the youtube channel. It's great by the way, I love it. I get to stand a bit away from the camera. You get to see a background and the sound is amazing. I don't think you can hear it autofocusing on my face. So definitely a top purchase of the year. Lives in support in accommodation, has a room, kitchen and bathroom. Happy there and has been there more than a year. Staff are okay and supportive. She doesn't take part in activities as she is busy. Studying content media and film production has towards hand uni three days a week. Two days a week this week! Because I had an x-ray on my dodgy knee. My knee is dodging. It keeps giving weight on me and I keep falling over. I'm not exactly the most mobile person at the minute. Happy at uni and is in a third year graduating next summer. It turns out she has a boyfriend. Not anymore. Well I don't have a boyfriend anymore. Visio is starting on the 5th of October for her knee. It just started hurting her accident or injury. Lydia was diagnosed with arthritis in her hands and ankles at the age of 17. She was supposed to write so she used a computer for everything. No medication for her. I guess it was an amateur pleat but it was stopped. Risks to self are currently low but remain dynamic and Lydia has a safety plan if she feels like self-harming. No various identifiers. Very pleasant and engaging young woman with normal speech. I don't know what to say. This word. No thought disorder. No psychotic symptoms. Cognition intact. Impression. Fortunately one stable oncology meant to have diagnosis required for the other consideration on next review. Patient has unexplained young officer arthritis in her hands and ankles. Now has 10 to half years of knee. May benefit from rheumatology appointment. Additional information. Produce plasma to 500 micrograms daily to be taken. One to be taken at night. Galithium levels done and blood and GP include kidney function, thyroid function and calcium. No other changes to medicine now. A way out come off as the end for knee. Crisis plan discussed and agreed to include the listening plasays. Continue care, coordinate and support. Men get medical review in three months to review men's again. Well that wasn't too bad. At least if I only accept my diagnosis. And to anyone who said I couldn't be diagnosed with these mental health issues at the same time. But you. So what do you think? To me that's just basic. Really? Yeah I would love to know your opinion in the description down below. Thanks for watching and if you have a new video request please leave them in comments down below. I'll see you guys in my next video. Peace.


Go ahead and get started so I don't keep you for the whole time if I don't have to. So thanks for coming this morning. So early. I'm Deborah Harrison for any of you who don't know me. I manage the clinical research support group here, which consists of five research coordinators and an upthalamic tech and a regulatory coordinator. And we work with all of the faculty and students, residents, fellows to help you do research and to do better research. So every year as I put this presentation together, I try to think of some, you know, some slides that might be a little more interesting or some topics that might be, you know, kind of get you interested at seven in the morning.  But nonetheless, I feel it's very valuable. And I'm hoping that, you know, I can get you to appreciate that as well. Mainly for a couple of reasons. I've been with the department, you know, in this kind of function for 25 years, believe it or not. And I can't believe it. And so I know firsthand that what, you know, what we do, what the coordinators do, what the regulations help do is create better quality research, which is really key. Why even do it if you're not going to do it well, right? And I do know also firsthand that it improves the experience for the patients who participate in research. Huge, makes a huge difference. So anyway, just to get started, you know, a couple definitions of what research is, even though everybody knows what research is. But the formal definition is that it's a systematic investigation designed to develop or contribute to generalizable knowledge. So there are really two points in that definition that I wanted to focus on. Of course, clinical research or human subjects research involves obtaining data from living individuals. And I highlight living because using decedents or samples from, I mean, data or samples from, decedents doesn't even qualify as human subjects research. That's just kind of basic research. And we can get into that when we get into the regs a little more. But and also want to emphasize not only is it data about living individuals, but that could just be data collection, even if you don't touch a patient that is considered human subjects research, as well as routine procedures, you know, where you're doing the typical evaluations that you do for research intent, as well as interactions, you know, drugs and delivery device treatments. So it doesn't have to be just a treatment trial to be considered applicable to the regulations. So in that first definition, when I talked about research being a systematic investigation, I wanted to focus on this just for a minute because what that implies is that it's something planned that you've given forth thought to, right? You've got a question. You've got a focused purpose. And frankly, it is time intensive. And as someone who has spent a lot of futile hours trying to collect data for a retrospective study from routine patient care charts, I can't apologize for research being time intensive because it's really difficult to get complete data, believe it or not, out of your standard patient care. You know, I think physicians are fabulous and amazing at remembering their patients, knowing their patients, you know, with a few cryptic notes in their medical record. But when you want to do research on that data, you'd be surprised, you know, what you actually find when you go in there and look. One of Dr. Olson's earlier studies on glistening, you would think with cataract patients, the number of surgeries we do here, getting 2,000 charts, you know, to include in your database would be no big deal. We were lucky to get 100 that had complete records in their standard of care records. So, you know, it really is a planned process, and it's very different from the usual way you interact with patients or collect their data, really. And the other thing is that no matter how good your patient notes are for that particular patient who's sitting in front of you, again, when you try to compile data to make some general statement about cataract lenses or, you know, whatever, it falls short, right? So, you really have to do some planned research up front that has a hypothesis and a study design appropriate to support that question, to obtain knowledge that is generalizable to all patients with C and V or whatever. So that's kind of the things that set research apart from your standard patient care. And the other thing which I think is a real challenge for investigators, and we see it all the time, when we're doing projects, some providers, physicians are good at this and others are not as good at it. It's something that I think you can cultivate, but when you're doing your standard care, as I said, you've got an individual patient in mind, and you're very familiar with the doctor-patient relationship and what all that involves. But when you're doing research and you're trying to gain generalizable knowledge, the individual treatment of that patient is not your prime focus. You're looking for results that you can apply across a broad population. And just because the individual therapeutic benefit to that patient sitting in front of you is not the prime focus, it doesn't mean that the risk to that patient is not your prime focus. That certainly gets into the study design where you're trying to obtain positive data about efficacy, for example, but safety for that patient is just as important. So when you're designing your study, when you're recruiting patients into a study, it's an equal consideration. And I will say that certain areas lend themselves more easily to research than others in this regard. A uveitis, for example, is so specialized, right? The drug regimens, the dosing, the frequency, the tapering, the adding of other treatments, really difficult to design those protocols and difficult to enroll in them. But nonetheless, you persevere and you get it. And because of these difference in focus, your relationship with a research participant who is also your patient changes a little bit. I think when you're doing research, you partner maybe a little bit more with that patient than you do when you've got their vision in your hands.  In a research protocol, they're participating with you in that protocol, right? Their compliance with the protocol, of course, it's always necessary for their own benefit and for their care, but it's essential for your research data as well. So things like informed consent, which I know carries over to your patient care as well, but becomes kind of a little bit bigger issue that they really understand what they're getting into when they're doing research. I'll give you a couple of examples of what is not research, and this is a regulatory definition, quality control. We've done projects here looking at the residency program. Residency programs across the country, certain parameters of what works and what doesn't work. The surgery center or the pharmacy will do QA types of projects where they actually do study their data and their processes, but that's not considered human subjects research. And case report forms, which the IRB defines as three or fewer patients. That's kind of interesting. That's great. It sounds kind of researchy. Here's something that's, you know, apart from our patient care, but nonetheless it's not considered a systematic investigation with only three patients. And I think that's why I know with Dr. Rwasco working with you all in developing research for your time here during your program, trying to get away from the presentation of case reports that, you know, clinical faculty day and residence day and focusing a little more on actual projects. This is a topic we could talk about in a whole nother session, but off-label use also is not considered research. If it's done within the practice of medicine, and you know better than I how widely drugs are used outside the product labeling for those things, which makes it difficult, for example, in UVitis to design protocols where you've got anti-inflammatories that are not approved for UVitis, but they're standard of care. And so you kind of have to walk a lot of different paths to get where you want to go with establishing a protocol in those areas. But most of the reasons, as you know, for using products off-label, you do use it for a clinical indication other than what it was actually studied for. You might use it in a different patient population. For the longest time, pediatric patients were given drugs that were never studied in pediatric patients. They were only studied in adults, and so the labeling was in adults. The dose or route of delivery right now, we're embarking on a couple projects in UVitis, which is investigating a suprachoroidal injection of triumcinolone. Triumcinolone, obviously, has been around forever. But even intravitreal injection is new, right, and was used, was done off-label for the longest time. Now there's a company who's formulated this long-standing, long-known, well-known product for a different type of injection. That would not be off-label use, but it could be if you were just trying it in your clinic. So to get to the kind of, you know, the basics that you've all seen before whenever you do any of the CITI training on clinical research or good clinical practices, why is research regulated? Oh, it's regulated for the reasons that anything is regulated. It kind of saves us from ourselves, right? People have biases, even well-intended people make mistakes, and they're conflicts of interest. I don't go over this case, which is kind of cited as the reason or the sentinel event that started the documentation of research regulations in this country. But if nothing else, you can see that the investigators had biases and prejudices about the people they were studying, and a conflict of interest that to them their research was more important than the patients they were studying. So really the regulations are designed to help us avoid those pitfalls, either intentional or intentional. And I'm sure you've all seen the Belmont report cited in any training you do on clinical research, and it really is the cornerstone of all of the research regulations. If you think of it, the ethical principles are the core values that we say we believe in when we're doing patient-centered research. The regulations are really the behaviors. If you say you believe in a respect for person, how do you show that respect to your patients by, you know, giving them informed consent by protecting their privacy? How do you show that you have their best interest at mind, even though they're participating in a larger project, by designing a study that minimizes their risks in order to, you know, maximize the benefits that you're going to get from that research?  And that's one of the ethical topics that comes up for the longest time. And if you have a disease for which there is no treatment, and all of a sudden there's this clinical trial, how motivated are patients to be in that clinical trial regardless of the risks to them? And so something that you have to guard against. And from the Belmont report, one of the first pieces of legislation that came into effect establishes institutional review boards or ethical review committees to review research. Everybody knows the IRB is a requirement, but it's actually regulated by the federal government in terms of how the IRB, who the IRB is composed of, how they conduct their meetings, how they conduct their reviews. And so they are as much regulated as they regulate us. And this common role of part of the Code of Federal Regulations that defines in great detail how IRBs review research. So I think you all know that you need to apply to the IRB for review of any research project that you're going to be doing, including retrospective research. And just to give you an idea of what the IRB is looking for in general when you're submitting those applications, as I mentioned before, that the risks to subjects is minimized compared to the value of the anticipated benefits of your research. I think for the longest time, investigators resented IRBs questioning their study design. They felt, I'm not harming these patients. These are our routine care. How can they question how many patients I've got enrolled? Well, if your research doesn't have the power to prove your question, why submit, you know, why subject patients to anything, even if it's just their standard care? And so you really, it's kind of the minimum necessary. The days of the kitchen sink protocols, let's throw in everything. The IRB looks at anything, a blood draw, sure it's minimal risk, but still it's not no risk to a patient, right? Dylating, not no risk. Florescene angiogram, again, it's an accepted risk to us in clinical practice, but when you look at a research protocol, you want to see that you're actually, there's a purpose for doing every procedure that you put in there. So if you have other things that are often called secondary outcomes, you know, not your primary, that's great, but just justify them. You know, tell them why you're looking at it as an exploratory, valuable, you want to see if it has an influence or is it just kind of a nice to know or really can you leave it out, you know? And then again, it comes back to the Belmont principle of beneficence. They're also looking for that you're selecting your subjects equitably. Informal consent is a huge, huge part of an IRB application. It's as much a part as the rest of the questions that you go through when you're filling out that application. And if you all were here at the Grand Rounds, where I can't remember the gentleman's name, who was the ethics guy from the American Academy, you talked about informed consent. I mean, I was sitting there thinking, well, that's exactly could be part of a research presentation as well, right? It's been a little kind of soft sold in clinical practice, but it's becoming obviously more important. But the federal regulations and the IRB, you know, we'll get to this, have a very specific list of things that you need to cover in an informed consent document for research.  And again, that speaks for the integrity and the kind of quality that your research will show. Also, protecting the privacy of subjects, we'll talk just for a second on HIPAA, which added a new dimension to research not too long ago. But in this day and age where, you know, genetic research is so important, I mean, privacy is a huge ethical consideration. It can't just be assumed that patients don't think about that because they certainly do, as you know. And as I mentioned, vulnerable populations, if you're looking at pediatric groups, patients with terminal diseases, prisoners, of course, you'd think, oh, that would be a great captive audience, no. Highly obviously subjected to coercion possibly. So as I mentioned, HIPAA, over 10 years old now, added another dimension to doing research because so much of what we do involves looking back through patient medical records to begin with, either as a complete project or even to identify people who would be appropriate to be in a prospective project. And I think physicians and institutions have always felt like that's our data. And what HIPAA tells us is no, that's the patient's data, right? I mean, yes, you are safeguarding it for them and you're creating that information, but nonetheless, we have to take certain precautions when we're dealing with patient information, as you know. At the University of Utah, the IRB was designated as the Privacy Board. That's not the case everywhere. But here, I mean, it makes it kind of nice for research because they have incorporated HIPAA questions as part of the IRB application and it's a one-stop kind of a review. You don't have to go to separate offices, one to do your IRB review and a separate office to do your HIPAA reprise review. So that's all included here. You all, I'm sure, are familiar with all the identifiers that make health information protected, health information under the HIPAA regulations. It's less common now, but occasionally, and actually I see this from dealing with people in industry, often they think, well, we don't have patient names on here, so it's de-identified. But if you're collecting the dates of their procedures or any of these other things, it could still be considered identifiable information. And it certainly doesn't mean that you can't do research with identified information. Actually, most of the research that we do is done with identifiable information. It just means that you either need to, in addition to obtaining consent from your participants, obtain their authorization as part of that consent process or request a waiver of authorization, which is very common in the research we do if we say, you know, we need to look at all of our cataract patients to determine who might be the appropriate population for this protocol. It would be impossible to call all of those patients and get their consent or authorization to do that. So for valid reasons, the IRB, the Privacy Board, will waive that authorization, right? But nonetheless, in the consent form, there is verbiage that talks about the use of their private information in the authorization section. You can get around, of course, HIPAA by using de-identified dataset, or you can use what's considered a limited dataset, which might contain one or two of those 18 identifiers, but not a fully identified dataset. Really, the only thing that that impacts you in doing research is if you are doing collaborative research with other institutions, there are guidelines about sharing information that differ between sharing fully identified information, a limited dataset, or a completely de-identified dataset. And there are legal documents that get involved at that point when you're transferring samples or sharing data between institutions.  And there's actually research, which is considered exempt from IRB oversight. The catch-22 here is that you still have to apply to the IRB for them to determine that it's exempt from their oversight. So, you know, retrospective chart reviews automatically fall into that category, but nonetheless, you have to explain your project to the IRB first. Educational and behavioral social sciences often fall under those kind of exemptions, or past specimens, for example. You don't have to do the usual continuing reviews with the IRB after you get that exempt determination. However, if you change your project significantly in terms of the risk-benefit ratio, the patients that you're looking at, or the procedures you're adding, usually if you're adding procedures, if you're taking away procedures, that's, you know, really not of significant interest. But so you might still have to submit amendments to the IRB to have them look at that project again, even if it's exempt. So they'll, at least, our IRB will send you kind of an annual email, you know, asking anything that you need to, you know, keep in mind that you've got this exempt protocol out there. Is there anything we need to know? And then I won't even get into the whole, you know, the purview of the FDA on products. But unfortunately, you know, it does come up, the IRB is the final arbiter of whether or not you can do a research project. But of course, the IRB, being regulated by the federal government, you know, is held to the standards that the FDA and the Department of Health and Human Services sets in code. And so if the IRB questions something, you're looking at using a drug off-label, and you don't want to just do it off-label in your patient population, you want to actually study it. The IRB will question whether or not you actually need an IND, an Investigational New Drug Exemption from the FDA, and we'll make you come up with it, either with an IND or a letter from the FDA stating that, no, it's not necessary. So depending on what you're doing recently, the refractive fellows wanted to look at. It wasn't topo-guided or one of the newer Lasik platforms, which I'm blanking on at the moment. And believe it or not, the labeling for that procedure was done with PRK, not with Lasik. But of course, the people are using it for Lasik. They wanted to study it and we said, oh gosh, that's a new indication, you know, for that, even though it's a software platform with that approved laser, the IRB is probably going to question whether or not you need an Investigational Device Exemption to do that. So it does come up even in your own, you know, investigator-initiated research. Here at the University, if you don't already know this, the IRB reports to the Associate Vice President for Research Integrity, who in turn reports to the VP for research. We have traditionally, forever, been required to use our local IRB. But in, I think it's December of this year, going into effect, new regulations by the NIH Department of Health and Human Services requiring a central IRB for collaborative projects that are funded by NIH, which we do several of. So this is going to be essentially, this will be new for us, that our IRB and other IRBs will defer their review to one designated IRB for a given project. Excuse me. Likewise, if you are doing a project and you want to add collaborators from other institutions, our IRB could be considered, you know, act as the central, the single IRB for those other institutions if they're willing to do that. So it's kind of new ground. We haven't used that model before. We're just getting into that with a couple of the projects that we've got coming up. So it'll be interesting. Hopefully, the intent is to save time in getting research up and going, getting it off the ground. The IRB, our IRB applications are done in this online system called AERICA. If you haven't been there, I think most of you probably have.  But the IRB website itself, which is separate from AERICA, is really a great site. And I don't expect you to really read this, but they've got all kind of guidance and template forms and links to the FDA, Health and Human Services, whatever, Department of Defense, specifically aimed at the investigators, even for research participants, references for, if you want to share with patients who you want to enroll in your studies. So really, if you have any questions, you can certainly come and ask the folks who work with me, but don't hesitate to go to the IRB website, which is, again, separate from AERICA. You don't have to start an application to start looking through what you're going to need to do an application. It's really well done. So we've talked about a little bit of the history of the regs briefly, why they're in place, your role as investigators, the role of the IRB in overseeing research, touched just basically on the informed consent process. And I say process because obviously talking to your patient, that discussion of informed consent is more than just giving them a form to sign. But having said that, when you're doing research, there are a lot of elements that should be, must be covered in that informed consent document if it's being reviewed by an IRB and you expect it to be approved by that IRB. And it's really pretty basic, explaining to the patients the background, the purpose why you're doing the research, what you hope to show by this research, what procedures they're going to undergo when they're in this protocol. You also want to tell them what their options are, what's available to them outside of the research project, not just focus on the research project. When we're doing trials of due drugs for CMV, for example, and it's gotten very difficult to recruit for those studies, obviously you have to tell patients, if we give you the sentence, you'll come in for three monthly injections and then we'll see you and if you don't need more as opposed to a new protocol, which typically the IRB requires monthly visits, monthly injections, they might be sham injections, so you've got to give the patient the full picture, not only of what you're doing as part of the research, but what they could have outside of the research project. And then, of course, you talk about the fact that it's voluntary, your relationship with them as their medical provider is not influenced by the fact whether or not they decide to participate, how you'll safeguard their confidentiality, if we're giving them any compensation, are you paying for any of their imaging procedures, for example, if they're in the research project, whereas, you know, if outside the research project they would be billed as standard of care, or you can do research and still bill for procedures that are standard, legitimately are standard of care, but patients need to know that.  So just kind of the most interesting part, I think, of the presentation, you know, the research is what it's about, right? That's the interesting part. The regs, the processes that you have to go through, I feel really strongly that it helps you develop quality research, but yet it's the research itself that's the really interesting part in why we do this, and I don't mean to imply that Leonardo da Vinci or Gregor Mandel did research at the University of Utah, but when I look back at the last 25 years, it almost seems that way to me. In 1992, which is when I was hired, we had essentially three research, clinical research projects ongoing. Dr. Olson always being at the forefront, and at the time of Mano Schwartz actually were looking at supplements. They were some of the first people who looked at supplements and how they affected antioxidants, how they affected your vision. Could they slow the progression of AMD or cataracts? I mean, it was kind of actually a large study, and in only the way that Dr. Olson can do, he got a lot of private funding from someone to help support that research, which unfortunately didn't prove its intended result. However, it did launch really a whole area of investigation which continues to this day. Dr. DeGree was involved in an NIH-sponsored trial of a surgical treatment for IONDT, which unfortunately proved that the surgical treatment made things worse than observation did, but how would you know? And Dr. Crandall always doing an IOP lowering meds for glaucoma. So that was it, believe it or not. Today, we have 83 IRB approved projects ongoing. About half of those are your projects, the projects that you're working on with faculty members, other projects that the faculty themselves have initiated, as opposed to the remainder which might be sponsored, meaning paid for, and probably written by either a private foundation, an NIH collaborative group, or industry pharmaceutical and device companies who are collecting data for hopefully FDA approval of new products. And so when I look back on this, I think how did we get from three projects to 83 projects? And some of it was, I think, happenstance as the department grew, obviously you bring in more faculty and they're going to want to do some research, they have some questions they want to answer. Paul Bernstein, he started right after I did, was really the big focus and still is the driving force behind clinical research. He's really gifted as a clinical researcher, can do that balance between clinical care and research in an amazing way. But really not too long after, what was it, five, six years after he got here, we were well positioned to be on that first wave of AMD trials. So the industry research was out there, it was advancing at that time. We did the first PDT trials, we were in the pivotal FDA trials for Lucentus and then ILEA. So we were well positioned to be on that first wave in retina, really the growth of retina research, which meant that our patients, of course, received those treatments sooner than the general population did. As we continued to grow with faculty, Dr. Olson was one of the first people on campus who saw the benefit of having someone like me in my group here to support investigators, to help them with all those time-consuming processes of IRB applications and the regulations. And I have to say the faculty, you hear about stories that faculty don't want to give up the control over their research projects. In the department, it was just, please help us do this. I mean, there was no hesitation whatsoever to the point where we, now, of course, we have context with biostatisticians, but really help in the development of those protocols and not just in the implementation of the protocols, which is nice. And then, you know, more recently, obviously with Dr. Ruwasco, we've come to spending more time with the residents and the fellows in helping you get a little more training and interest in doing your own research when you're finished with your program. Just a little bit of a history. I think one of the more interesting things in terms of longevity, which started before I was here either, before Dr. Hoffman was even here, were the early cryotherapy treatments for ROP. The Dr. Hoffman's predecessors were involved in the NIH collaborative study, the first one. Then when Dr. Hoffman was here at a later date, after they had established treatment guidelines for cryotherapy, then they started questioning, well, would patients benefit from earlier treatment than what the standard of care is? There was another NIH collaborative trial for that that we were a part of. Recently, we've been looking at and has shown, introducing the red cam, the fundus photos, into the NICU, into the ROP exams, to not only document your exams, but the chair of this trial at CHOP, his impetus, he does a lot of humanitarian work. He goes to third-world countries where there aren't pediatric ophthalmologists to look at these babies. And so really, his interest was in developing a telemedicine approach for diagnosing ROP. And even in this country, as fewer pediatric ophthalmologists are getting into ROP, don't have the expertise, maybe, that Dr. Hoffman does and other pediatrics here, to utilize telemedicine to help their patients. Right now, we're looking at a project, looking at growth parameters, which have shown to be predictive of infants at most risk for ROP, another NIH collaborative trial. And we're also finally starting to do a Vastin and Lucentus treatment trials for ROP. For the longest time, you know, the risk of those trials is tremendous. Dose is extremely important when you've got developing infants. You don't want to mess with their normal development. And so Dr. Hartnett elected to really not get into that too much until we had controlled clinical trials to give us data of what the appropriate process is for that, which we've got ongoing right now. And, you know, with all of clinical research, as I said, the research is the interesting part. We've really made a difference, as you can see with ROP, inpatient care. It has advanced patient care. It has improved patient care. Right, the enubitis mentioned, you know, quickly that the start of Vigidine PDT and then the anti-VegFs really launched that field. Geographic atrophy is still a holy grail out there. We get different trials that we're looking at. Treatments for geographic atrophy, obviously nothing is yet FDA approved for that. And then the orphan retinal diseases right now are a big interest because those single gene mutations are the ones that are most amenable to gene therapy, right? So that's going to kind of be the next way. That's what we're seeing. We've got a couple Corridorimia natural history studies going on right now with companies who are developing gene therapy products for them. And so that's kind of exciting. Mac-Tel, if you know Mac-Tel, Mac-Luric-Langentasia type 2, at some point I think Dr. Bernstein will probably be doing another grand rounds on that because he's doing some really cool imaging right now of those patients, which the exact cause of that disease is unknown. The symptoms, of course, I mean the signs are known, but might help lead to that causation and with the help of the Utah population database, here in Utah, there's always been this feeling that it's a genetic disorder, but we're actually the first center in the world who's developing these large pedigrees of families with multiple affected family members, which is really cool. And so we're working on the genetics of that. The uveitis I mentioned are always a challenge. There are NIH collaborative trials going on around the treatment of uveitis, comparing treatments for uveitis, and Dr. Battali's been a real leader in that group. And recently we did a completed a trial for Adalibamab, which was just recently FDA approved for uveitis. Again, one of those things that was probably used off-label, but then Abbott saw the usefulness of actually applying to the FDA for approval for a new indication, and it turns out it worked really well. And then, of course, you know, the interior segment has been a long-standing research endeavor and interest at the department here. Most people have probably never heard of the CLEC study in 1995, which was looking at how to best care for vision, how to best manage the vision of care to common patients, how to best fit contact lenses. It's the first NIH grant awarded to optometrists, and under Harold Wolfson, we were able to participate in that. And then more recently, even though corneal cross-linking has been used around the world, it hasn't been FDA approved in the U.S., and we completed one of the trials, you know, pivotal FDA approval trials for that recently.  I mean, recruitment was not even a question. But of course you know that with Dr. Olson, Dr. Mamelas, Dr. Crandall, the field of cataract surgery is a totally different place than it was before they started doing their practice and doing their research. Anything from topical anesthetic, as opposed to retro ball bar for cataract surgery, to the anti-inflammatory agents that used irrigating solutions now to the IOLs themselves. Dr. Olson apparently coined the phrase dysphotopsia. He made up that word himself, but now it's kind of a standard part of the jargon. You know, that's thanks to our research here. So basically that's the overview. I know I skipped a lot of the details, but hopefully if you have any particular, any specific questions, you won't have to take to come to our group, which I've kind of shown up there with our coordinators, technicians, and regulatory coordinator. Dr. Bernstein does actually have an official position as the medical director for clinical research. And then Dr. Mawasko, of course, is in our position functioning in the education program for bringing more research involvement into our residency and partnership program. So that's our group. I think, as I said, I think, you know, we feel like even though research administration sounds kind of, you know, of a boring topic, my group is very dedicated, very dedicated to the research and as well as the patients. Love to do this kind of work. Love to work with you all. So please don't hesitate to come and let us help you hold your patients. Any questions about anything? Great. Well, thanks for being here so early. I guess you don't have a choice, but I appreciate it nonetheless. Thank you.


Not this one. Oh, it's electric. Oh, I missed my novel. No, so bad Can it come here? Yeah, but there's a sucker somewhere. Watch it.  I'll shoot this guy. I feared. Got the sucker bus. Yeah, okay. He's already summoning a new one. Oh, it is rested, dude.  No, it's fine. I mean let's just wait, okay? Like we wasted the unscathed. Blinding fear. I wasted my pet. You want to go sham?  Okay, seduce me. I can stop this. Bear everything. Yeah, go pet. I'll get pet action, yeah. Yeah, I'm hitting it. I can shoot. Should I? Sure. I'll maybe try to link this. What? I'm gonna hit you. Got it. Don't shaman? Yeah. Yeah, I don't know if I'll get it. Shoot this guy. Keep this guy.  Burning sham. Yeah, yeah, I'm gonna have everything. I'm exed, but I think it should break. I'm gonna look for drink here. Looking for drink. I'll jump down even. Rain is not hitting me. He's trying hard to hit it, but I'm getting mana. You know where to get your hands. I don't want to ship there. I want to start with a ship on the shaman. The tremor is in the pillar. I can't do anything to it. Maybe it's not actually. He sees me, he sees me. I'm in the lane. I can ship someone now. Getting fear too. I'll just will. I cannot ship the shaman. Watch out. Am I? Yeah. Maybe I can double here. Going on the pet. I can also burn. Burning. I'm gonna do damage instead. Can you deep? Yeah, I can't. I know no procs and I don't want to pop. I'm gonna get another burn. No, I'm not. I'm trying now. I can ship shaman now. I forced everything. I can't. I'll try shipping. I got it. I'm gonna try and fear. Yeah. No, I can't. I can't. I'll just will. No, I don't have it. You need to be careful. I'm not gonna shrink it. Yeah, I can block. Yeah, let's do it. I think we have to do damage go on shaman. I don't think we're gonna... Yeah, exactly. Got you. Okay, okay. Should I block? Yeah, I'll block you. Let's go. Let's do damage go on that. I know there's no dots, but you still gonna use everything. Or is that... You know they... They underestimate damage so much.  They just died. I'll get in combat for them. Yep. One now. Staying back. I might keep this guy here. We're gonna split up anyways. He never did that right now.  I'll stay with these children. Send the game girl. Wriggle me? Going in, going in. Holding, holding. I'm dipping right here. I can't actually. I don't have it. I'm not using anything. I still have buffs. He dotted me. I can ship. I can keep right here. I got his damage. I don't have dip for the road. Can you leave maybe? They go all in on me okay? Yeah, yeah. Yeah, I got a rocket on him. I can dot him maybe. He vanished, he vanished. That's the last vanish. Come up a bit maybe. I'll come you. Burning priest, burning priest. I cancel, I cancel, I cancel. Yeah, I'm gonna do an eye, doing an eye. Re-shipping? Re-shipping? Cast damage on him, cast damage on him. Because I have two dips, right? I can keep the rocket though. Sheep's on me. Okay, yeah, sure. I'll check out this. Trinket, just for you. Yeah. I'm not dipping right here, I guess. Trinket again? Yeah. Probably better. He went up bro. It's kind of deep. Okay, but I have luck help. Yeah. It looks so aggro. Sheep's again. Send us, get me. Right? Yeah, priest wants to fear me. I'll fear him then. I'll ship this guy. Priest trinket. Oh, I was ranged for sheep. So sad. It's fine. I'll be on the top. But I'm fine. I'll stop the Reaker. Actually, I'm not stopping. Yeah, that's fine. I'll just stop some later or something.  They'll be here. I think they'll go me now. Or maybe not. I think as soon as Mage dispels all the boxes, it's okay. I'm just starting a bit faster. I'm going in now. Get me? Yeah. Is this spelling Mage? I should. Mage is too far from me. Anybody? Good link. I can stop this. I'm going to ship. Take a mage. I'm just going to stall them. You have just soon? Yeah, I know. Take a mage. I'll give you a piece. It's okay. What are we doing? It's spelling DK. I'm not going to kill him. It's spelling power. It's because it's sending power. It's trying me, it's trying me. Yeah, I'm fine. I'm fine. It's crazy. I'm going to do a rescue. I can ship. Get trinket this. I'll number this guy. Yes. I'll give CS a trinket. I'm sending, okay? But a lot of stuff are hitting me. A piece as well? I'm done with that. You ready? Yeah. No one on. No one on. CS now is coming. Got it. I hope you can steer right after it. Got it. I'll ship. Yeah. Yeah. Link down. Okay. Throw a trinket. I'll see what you've done. I need to ship that. Yeah, do it. Yes. Otherwise. We got the worry trinket. It's all fine. I know why. I'll ship now. I'll ship. MC warrior. I'm sure. He has no way to protect. Where are you MC? Got him. Yeah. He's going to stun you. You're all right. He's stunned you. Yeah, I'll fire an A. I'll ship now. Got it. Pick down. I feel I'm going to do something. Get it. Get it. Nice. Like a couple of tourneys. Maybe. But you could have watched online anyway. But all of their IPs are dying. So it's not worth it. Try not to get slow. Yeah. Yeah. Ready. Should get fear. Wait me. I'll do it. I'll do it. I need to be safe. Yeah. Not just. I'll ship now. I'll do it now. I'll do it. Okay. I'll pick the creeper. I think. I used cities now. Yeah. Because I think we can cross. I'll never say it's at the end of the freedom. Careful. Block if you need to. Am I fine? Yeah, I'll block you. I'll fill power. Yeah, sure. I'll never worry about it. I'll cast MCS. It'll dip. Rub it like this. Miss K. You need to get it. Got it. Sheeper or sheeper? No more. I mean the palace. No more this guy. Where is Trinket? Okay. Yeah. He did it. Yeah. I can fairly soon. Yeah, yeah. I'll push it. Push it. Ready? Yes, yes, yes. Casting now. Going. Go. We can kill, okay? But I have no procs for that support. I got it. Got it. Got it. Get it now. I need to be careful for him. Nice. That's nice. I actually did damage. Actually, if you didn't do damage here, there's no more.  So, you know. I'm full sending him every time, bro.